Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Assets (2016 - 2025)

United Therapeutics (UTHR) has disclosed Non-Current Assets for 17 consecutive years, with $4.2 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 19.7% to $4.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.9 billion through Dec 2025, up 22.81% year-over-year, with the annual reading at $4.2 billion for FY2025, 19.7% up from the prior year.
  • Non-Current Assets hit $4.2 billion in Q4 2025 for United Therapeutics, up from $3.9 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.2 billion in Q4 2025 to a low of $780.9 million in Q4 2021.
  • Historically, Non-Current Assets has averaged $2.9 billion across 5 years, with a median of $3.1 billion in 2024.
  • Biggest five-year swings in Non-Current Assets: crashed 68.1% in 2021 and later surged 226.24% in 2024.
  • Year by year, Non-Current Assets stood at $780.9 million in 2021, then rose by 13.16% to $883.7 million in 2022, then rose by 21.06% to $1.1 billion in 2023, then soared by 226.24% to $3.5 billion in 2024, then grew by 19.7% to $4.2 billion in 2025.
  • Business Quant data shows Non-Current Assets for UTHR at $4.2 billion in Q4 2025, $3.9 billion in Q3 2025, and $4.1 billion in Q2 2025.